Follow Us TR

News Details

Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy

About Akcea Therapeutics, Inc.
  • NASDAQ: $AKCA
  • Notified: $14.90
  • 07:02 EDT

Price Chart